Dose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma with a poor prognosis: A phase II multicenter study

Haematologica

Volumn 94, Issue 9, 2009, Pages 1250-1258

  Vitolo, Umberto ^a,l   Chiappella, Annalisa ^a   Angelucci, Emanuele ^b   Rossi, Giuseppe ^c   Liberati, Anna Marina ^d   Cabras, Maria Giuseppina ^b   Botto, Barbara ^a   Ciccone, Giovannino ^a   Gaidano, Gianluca ^e   Falchi, Lorenzo ^d   Freilone, Roberto ^a   Novero, Domenico ^f   Orsucci, Lorella ^a   Pavone, Vincenzo ^g   Pogliani, Enrico ^h   Rota Scalabrini, Delia ⁱ   Salvi, Flavia ^j   Tonso, Anna ^k   Tucci, Alessandra ^c   Levis, Alessandro ^j  

^a Azienda Ospedaliera Universitaria San Giovanni Battista   (Italy)

^b Ospedale Oncologico A Businco   (Italy)

^c SPEDALI CIVILI   (Italy)

^d POLICLINICO MONTELUCE   (Italy)

^e UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^f UNIVERSITY OF TURIN   (Italy)

^g POLICLINICO   (Italy)

^h S Gerardo dei Tintori   (Italy)

ⁱ CANDIOLO CANCER INSTITUTE   (Italy)

^j Divisione di Ematologia   (Italy)

^k OSPEDALE DEGLI INFERMI   (Italy)

^l MOLINETTE HOSPITAL   (Italy)

more..

Author keywords

Autologous stem cell transplantation; Diffuse large B cell lymphoma; Dose dense chemotherapy; High dose chemotherapy; Poor prognosis; Rituximab

Indexed keywords

ANTINEOPLASTIC AGENT; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; EPIRUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; MITOXANTRONE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; B LYMPHOCYTE; BACTERIAL MENINGITIS; BACTERIAL PNEUMONIA; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; DRUG TREATMENT FAILURE; ENGRAFTMENT; ESCHERICHIA COLI INFECTION; GASTROINTESTINAL TOXICITY; HERPES ZOSTER; HIGH RISK PATIENT; HUMAN; INFECTION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYELOABLATIVE CONDITIONING; NEPHROTOXICITY; NEUROLOGIC DISEASE; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROGNOSIS; PSEUDOMONAS INFECTION; PYREXIA IDIOPATHICA; RANDOMIZED CONTROLLED TRIAL; SEPSIS; STAPHYLOCOCCUS INFECTION; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS;

EID: 70349128174     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.007005     Document Type: Article

References (45)

1. Shipp MA, Harrington DP. A predictive model for aggressive NHL: the international non-Hodgkin's lymphoma prognostic factors project. N Engl J Med 1993;329:987-994
2. Coltman AC Jr, Dahlberg S, Jones ES. CHOP is curative in thirty per cent of patients with large cell lymphoma: a twelve year Southwest Oncology Group follow-up, in Skarin AT (ed): Advances in Cancer Chemotherapy: Update on Treatment for Diffuse Large Cell Lymphoma. New York, NY; Park Row 1986. p. 71-77
3. Fisher RI, Gaynor ER, Dahlberg R, Oken MM, Grogan TM, Mize EM, et al. Comparison of standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993;328:1002-1006
4. Philip T, Guglielmi C, Hagenbeek A, Somers R, van Der Lelie H, Bron D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non- Hodgkin's lymphoma. N Engl J Med 1995;333:1540-1545
5. Gianni AM, Bregni M, Siena S, Brambilla C, Di Nicola M, Lombardi F, et al. High dose chemotherapy and autologous bone marrow transplantation compared with MACOPB in aggressive B-cell lymphoma. N Engl J Med 1997;336:1290-1297 (Pubitemid 27187782)
6. Haioun C, Lepage E, Gisselbrecht C, Salles G, Coiffier B, Brice P, et al. Survival benefit of high dose therapy in poor risk non Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol, a groupe d'Etude des Lymphomes de l'Adulte study. J Clin Oncol 2000;18:3025-3030 (Pubitemid 30644128)
7. Milpied N, Deconinck E, Gaillard F, Delwail V, Foussard C, Berthou C, et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 2004;350:1287-1295 (Pubitemid 38375363)
8. Martelli M, Gherlinzoni F, De Renzo A, Zinzani PL, De Vivo A, Cantonetti M, et al. Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomised trial. J Clin Oncol 2003;21:1255-1262 (Pubitemid 46606401)
9. Vitolo U, Liberati AM, Cabras MG, Federico M, Angelucci E, Baldini L, et al. High dose sequential chemotherapy with autologous transplantation versus dose-dense chemotherapy MegaCEOP as first line treatment in poor-prognosis diffuse large cell lymphoma: an "Intergruppo Italiano Linfomi" randomized trial. Haematologica 2005;90:793-801.
10. Strehl J, Mey U, Glasmacher A, Djulbegovic B, Mayr C, Gorschluter M, et al. High-dose chemotherapy followed by autologous stem cell transplantation as first-line therapy in aggressive non-Hodgkin's lymphoma: a meta-analysis. Haematologica 2003;88:1304-1315 (Pubitemid 37456386)
11. Greb A, Bohlius J, Trelle S, Schiefer D, De Souza CA, Gisselbrecht C, et al. High-dose chemotherapy with autologous stem cell support in firstline treatment of aggressive non- Hodgkin lymphoma - results of a comprehensive meta-analysis. Cancer Treat Rev 2007;33:338-346 (Pubitemid 46778207)
12. Vose JM, Link BJ, Grossbard M, Czuczman M, Grillo-Lopez A, Gilman P, et al. Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non- Hodgkin's lymphoma. J Clin Oncol 2001;19:389-397 (Pubitemid 32112850)
13. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-242 (Pubitemid 34438862)
14. Pfreundschuh M, Shubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ Bcell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008;9:105-116
15. Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) group. Lancet Oncol 2006;7:379-391
16. Brusamolino E, Rusconi C, Montalbetti L, Gargantini L, Uziel L, Pinotti G, et al. Dose-dense RCHOP- 14 supported by pegfilgrastim in patients with diffuse large Bcell lymphoma: a phase II study of feasibility and toxicity. Haematologica 2006;91:496-502.
17. Halaas JL, Moskowitz CH, Horwitz S, Portlock C, Noy A, Straus D, et al. R-CHOP-14 in patients with diffuse large B-cell lymphoma: feasibility and preliminary efficacy. Leuk Lymphoma 2005;46:541-547 (Pubitemid 40584870)
18. Vitolo U, Cortelazzo S, Liberati AM, Freilone R, Falda M, Bertini M, et al. Intensified and high dose chemotherapy with granulocyte colony-stimulating factor and autologous stem-cell transplantation support as first-line therapy in high-risk diffuse large-cell lymphoma. J Clin Oncol 1997;15:491-498 (Pubitemid 27074215)
19. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994;84:1361-1392 (Pubitemid 24273002)
20. Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007;109:1857-1861.
21. Mills W, Chopra R, McMillan A, Pearce R, Linch DC, Goldstone AH. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol 1995;13:588-595
22. Klimo P, Connors JM. MACOP-B chemotherapy for the treatment of advanced diffuse large cell lymphoma. Ann Intern Med 1985;102:596-602. (Pubitemid 15120476)
23. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an International Workshop to standardize response criteria for non Hodgkin's lymphomas. J Clin Oncol 1999;17:1244-1253 (Pubitemid 29162950)
24. Kaplan EL, Meier P. Nonparametric estimation from incomplete information. J Am Stat Assoct 1958;53:547-581
25. Cox DR. Regression model and life tables (with discussion). JR Stat Soc 1972;34:187-222
26. Hoerr AL, Gao F, Hidalgo J, Tiwari D, Blum KA, Mathews V, et al. Effects of pretransplantation treatment with rituximab on outcomes of autologous stem-cell transplantation for non-Hodgkin's lymphoma. J Clin Oncol 2004;22:4561-4566 (Pubitemid 41185123)
27. Khouri IF, Saliba RM, Hosing C, Okoroji GJ, Acholonu S, Anderlini P, et al. Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphoma. J Clin Oncol 2005;23:2240-2247 (Pubitemid 46218716)
28. Tarella C, Zanni M, Magni M, Benedetti F, Patti C, Barbui T, et al. Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innnovative nei Linfomi survey. J Clin Oncol 2008;26:3166-3175
29. Vellenga E, van Putten WLJ, van't Veer MB, Zijlstra JM, Fibbe WE, van Oers MHJ, et al. Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial. Blood 2008;111:537-543
30. Tarella C, Zanni M, Di Nicola M, Patti C, Calvi R, Pescarollo A, et al. Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab- supplemented, early intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi). Leukemia 2007;21:1802-1811
31. Gisselbrecht C, Fitoussi O, Belhadj K, Mounier N, Feugier P, Coiffier B, et al. Survival impact of rituximab combined to ACVBP (R-ACVBP) in 209 poor risk diffuse large B-cell lymphoma (DLBCL) patients treated with upfront high-dose consolidative autotransplantation (HDC): a GELA phase II study. Blood 2008;112:771.
32. Glass B, Kloess M, Reisen M, Metzner B, Trumper L, Loffler M, et al. Repetitive high-dose therapy followed by autologous stem cell transplantation (MegaCHOEP) for primary treatment of aggressive NHL: the impact of rituximab on outcome and toxicity. Bone Marrow Transplant 2006;37:239.
33. Kamezaki K, Kikushige Y, Numata A, Miyamoto T, Takase K, Henzan H, et al. Rituximab does not compromise the mobilization and engraftment of autologous peripheral blood stem cells in diffuse-large B-cell lymphoma. Bone Marrow Transplant 2007;39:523-527 (Pubitemid 46629587)
34. Benekli M, Hahn T, Shafi F, Qureshi A, Alam AR, Czuczman MS, et al. Effect of rituximab on peripheral blood stem cell mobilization and engraftment kinetics in non- Hodgkin's lymphoma patients. Bone Marrow Transplant 2003;32:139-143 (Pubitemid 36903436)
35. Horwitz SM, Negrin RS, Blume KG, Breslin S, Stuart MJ, Stockerl- Goldstein KE, et al. Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non- Hodgkin lymphoma. Blood 2004;103:777-783 (Pubitemid 38129532)
36. Glass B, Kloess M, Bentz M, Schlimok G, Berdel WE, Feller A, et al. Dose-escalated CHOP plus etoposide (MegaCHOEP) followed by repeated stem cell transplantation for primary treatment of aggressive high-risk non-Hodgkin lymphoma. Blood 2006;107:3058-3064
37. Kaiser U, Uebelacker I, Abel U, Birkmann J, Trumper L, Schmalenberg H, et al. Randomized study to evaluate the use of highdose therapy as part of primary treatment for "aggressive" lymphoma. J Clin Oncol 2002;20:4413-4419
38. Stewart DA, Bahlis N, Valentine K, Balogh A, Savoie L, Morris DG, et al. Upfront high-dose chemotherapy with DICEP followed by BEAM and autologous stem cell transplantation for poor-prognosis aggressive non- Hodgkin's lymphoma. Blood 2006;107:4623-4627 (Pubitemid 43882606)
39. Sehn LH, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K, Klasa R, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large Bcell lymphoma in British Columbia. J Clin Oncol 2005;23: 5027-5033 (Pubitemid 46224009)
40. Malumbres R, Chen J, Tibshirani R, Johnson NA, Sehn LH, Natkunam Y, et al. Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. Blood 2008;111:5509-5514
41. Rimsza LM, Leblanc ML, Unger JM, Miller TP, Grogan TM, Persky DO, et al. Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP. Blood 2008;112:3425-3433
42. Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, et al. Stromal gene signature in large B-cell lymphomas. N Engl J Med 2008;359:2313-2323
43. Dupuis J, Gaulard P, Hemery F, Itti E, Gisselbrecht C, Rahmouni A, et al. Respective prognostic values of germinal center phenotype and early (18)fluorodeoxyglucose-positron emission tomography scanning in previously untreated patients with diffuse large B-cell lymphoma. Haematologica 2007;92:778-783
44. Gallamini A, Hutchings M, Rigacci L, Specht L, Merli F, Hansen M, et al. Early interim 2-[18F]fluoro-2-deoxy- D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian- Danish study. J Clin Oncol 2007;25:3746-3752 (Pubitemid 47372616)
45. Cashen A, Dehdashti F, Luo J, Bartlett NL. Poor predictive value of FDG-PET/CT performed after 2 cycles of R-CHOP in patients with diffuse large B-cell lymphoma (DLCL). Blood 2008;112:371.